Leigh Ann Bruhn, director of Avalere Health, addresses results from "DIMENSIONS of Specialty Pharmaceuticals: Evolving Trends in Market Access," a new study conducted by Avalere Health and commissioned by Janssen Biotech, Inc. and Johnson & Johnson Health Care Systems.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More